Categories: ImplantsNews

IMPLANET Announces Its 2025 Financial Calendar

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:


IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its schedule for the publication of financial information for 2025.

Events

Dates*

2024 Full-Year Revenue

January 14, 2025

2024 Full-Year Results

March 4, 2025

Annual General Meeting

March 28, 2025

2025 First-Quarter Revenue

April 9, 2025

2025 First-Half Revenue

July 8, 2025

2025 First-Half Results

September 16, 2025

2025 Third-Quarter Revenue

October 7, 2025

(*) Subject to change. Press releases will be issued after market close.

Upcoming financial publication

  • 2024 Full-Year Revenue, on January 14, 2025 after market

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributing medical technology equipment. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. In 2022, IMPLANET entered into a commercial, technological and financial partnership with SANYOU MEDICAL, China’s second largest medical device manufacturer. IMPLANET employs 43 staff and recorded a consolidated revenue of €7.4 million in 2023. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris.

For further information, please visit www.Implanet.com.

Contacts

IMPLANET
Ludovic Lastennet, CEO

David Dieumegard, CFO

Tél. : +33 (0)5 57 99 55 55

investors@Implanet.com

NewCap
Investor Relations

Nicolas Fossiez

Tél.: +33 (0)1 44 71 94 94

Implanet@newcap.eu

NewCap
Media Relations

Arthur Rouillé

Tél.: +33 (0)1 44 71 94 94

Implanet@newcap.eu

Staff

Recent Posts

Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt

Burlington, Ontario--(Newsfile Corp. - January 7, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT"…

4 hours ago

TE Connectivity earns top score from Human Rights Campaign Foundation

2025 Corporate Equality Index assesses LGBTQ+ workplace equality GALWAY, Ireland, Jan. 7, 2025 /PRNewswire/ --…

4 hours ago

Education Management Solutions Announces Nominees for 16th Annual Excellence in Clinical Simulation Awards

A Representation of the Best in Simulation Healthcare Education in 2024  ORLANDO, Fla., Jan. 7,…

4 hours ago

University Lab Partners Names Sandra J. Miller as Executive Director to Advance Life Sciences Innovation

Innovation & Entrepreneurship Leader to Accelerate ULP's Mission in Incubation, Acceleration, and Education IRVINE, Calif., Jan.…

4 hours ago

Therap Services Introduces Daily MAR to Enhance Person-Centered Care, allowing Users to Record Medications for Specific Dates

TORRINGTON, Conn., Jan. 7, 2025 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…

4 hours ago